Regeneron Pharmaceuticals (REGN) Depreciation & Amortization (CF) (2009 - 2026)

Regeneron Pharmaceuticals' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $123.2 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 2.92% year-over-year to $123.2 million; the TTM figure through Mar 2026 stood at $540.0 million (up 8.94% YoY), while the FY2025 annual figure was $543.7 million, up 12.59% from the prior year.
• Depreciation & Amortization (CF) was $123.2 million for Q1 2026 at Regeneron Pharmaceuticals, down from $145.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $145.0 million in Q4 2025 to a low of $74.3 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $112.5 million across 5 years, with a median of $114.1 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) soared 38.58% in 2023, then declined 2.92% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $100.1 million in 2022, then rose by 12.89% to $113.0 million in 2023, then increased by 11.86% to $126.4 million in 2024, then increased by 14.72% to $145.0 million in 2025, then fell by 15.03% to $123.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $123.2 million (Q1 2026), $145.0 million (Q4 2025), and $136.7 million (Q3 2025), per Business Quant data.